The company will continue to invest in both its generic and innovative products pipeline
Sun Pharmaceutical Industries Limited expects its research spending to be about 6 to 7 per cent of sales for the financial year 2027, Dilip Shanghvi, Sun Pharma’s founder and Executive Chairman said, after the company had announced its financial performance for the year ended March 31, 2026.
The company will continue to invest in both its generic and innovative products pipeline, he told analysts, adding that in the year under review about 36 per cent of the spending was on innovative products.
On the $11.75 billion deal to acquire Organon, that was announced last month, Shanghvi said, “we have set up an integration management office and have initiated activities for day one preparedness. The regulatory filings in various markets is in progress. We expect the acquisition to be completed in Q4 FY27.”
Financial performance
Earlier in the day, Sun Pharma had announced details of its financial performance and the company said it clocked a 26.2 per cent growth in net profit, at ₹2,714 crore, for the fourth quarter ended March 31, 2026. The drugmaker’s sales for the fourth quarter stood at ₹14,559 crore, up 13.6 per cent. Its global innovative medicines (formerly specialty medicines) sales was $354 million. This was up 20.1 per cent and accounted for 22.2 per cent of sales, it said.
Sun’s R&D investment for the quarter under review was ₹975 crore, 6.7 per cent of sales. For the entire year, the spending stood at ₹3,554 crore, 6.1 per cent of sales.
Kirti Ganorkar, Sun Managing Director, said, “our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our US Innovative medicines business has surpassed $1 billion in revenues, while ex-US innovative medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”
For the year ended March 31, 2026 (FY26), the company’s net profit was up 5 percent, at $11,479 crore. Its sales stood at $58,220 crore, up 11.9 per cent. Its global innovative medicines sales clocked $ 1,420 million, up 16.4 per cent and accounting for 20.7 per cent of sales, both ex-milestone, the company said.
The company’s board of directors proposed a final dividend of ₹5 per share for the year FY26. This is in addition to the interim dividend of ₹11 per share paid in FY26, taking the total dividend for FY26 to ₹16 per share, same as FY25, the company said.
Published on May 22, 2026
